Clinical Guidelines of Treatment of Obesity in Adults
Journal of the Korean Medical Association
;
: 345-356, 2003.
Article
in Korean
| WPRIM
| ID: wpr-151125
ABSTRACT
Obesity increases the risk of serious medical conditions such as type 2 diabetes and coronary heart disease. The risks associated with comorbidities can be reduced with a modest weight loss. Obesity should be recognized and treated as a chronic, progressive, and relapsing disease. The management of obesity requires a long-term approach that is tailored to an individual's lifestyle and needs. Initial treatment should focus on lifestyle changes, i.e., reduced calorie intake and increased physical activity, with behavior modification strategies. Medications may be used adjunctively. Most of FDA-approved anti-obesity drugs should be prescribed for short-term weight loss. Recently, sibutramine and orlistat were approved for long-term weight loss and maintenance. In addition to weight reduction, sibutramine and orlistat provided beneficial effects on cardiovascular risk factors in clinical trials. Several drugs, such as fluoxetine, bupropion and topiramate, approved for other uses, have shown weight loss in some clinical trials. Surgical treatment should be reserved for severely obese patients with significant medical comorbidities or physical conditions.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Behavior Therapy
/
Weight Loss
/
Comorbidity
/
Fluoxetine
/
Risk Factors
/
Bupropion
/
Anti-Obesity Agents
/
Coronary Disease
/
Life Style
/
Motor Activity
Type of study:
Etiology study
/
Practice guideline
/
Risk factors
Limits:
Adult
/
Humans
Language:
Korean
Journal:
Journal of the Korean Medical Association
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS